Endymed Expands Its Operation in North America

Welcomes Bill Scott as Endymed's US Subsidiary President

Endymed Ltd (TASE: ENDY), currently traded on Tel Aviv Stock Exchange, is pleased to announce the appointment of Bill Scott as President of its US subsidiary, Endymed Inc.

As president of Endymed Inc. Bill will be responsible for leading Endymed’s sales teams in the United States, ensuring customers receive the highest standards of sales and account management support. Mr. Scott was selected to lead the Company’s operations in the United States and Canada as part of the Company’s growth plan of expanding its operations in North America, and in particular the United States. With experience spanning over 25 years in the medical esthetics field, Bill’s leadership and expertise will be invaluable to Endymed’s growth.

A dynamic leader providing support designed for success and growth within the organization. Bill strategically focused on increasing productivity that benefits the bottom-line. Bill possess a deep passion for sales in the aesthetic and surgical arena while developing relationships that promotes long-term progress. While at Palomar Medical, he served as West U.S. and Canada Sales Director. Bill’s team was consistently recognized as the #1 region in sales. In 2013, Bill was recruited as North American VP of Sales at Alma. After rebuilding and stabilizing the sales force, the company attained annual double-digit growth achieving a successful IPO launch in 2017 – more than doubling its valuation. . Most recently, as VP North America Sales at Viora Medical, Bill supported historic revenue growth that followed with an acquisition resulting from success in the U.S. market.

Bill’s proven core competencies include team turnaround leadership focused on sales revenue, sales training, team building & new product launches. Bill is motivated to continue the excellence at Endymed and supporting the team in building a world-class sales organization. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a significant reach in the North American market.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.